{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Columbus",
      "state": "OH",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "76636",
      "recalling_firm": "Amerisource Health Services",
      "address_1": "2550 John Glenn Ave Ste A",
      "address_2": "N/A",
      "postal_code": "43217-1188",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide",
      "recall_number": "D-0520-2017",
      "product_description": "GlipiZIDE Extended-release tablets, 2.5 mg, 30-count carton (NDC 68084-295-21), Individual dose (NDC 68084-395-11), Rx Only, Packaged and Distributed by American Health Packaging, Columbus, Ohio 43217, NDC 68084-295-21",
      "product_quantity": "19,393 cartons (581,790 extended release tablets)",
      "reason_for_recall": "Failed dissolution specifications: Glipizide 2.5 mg ER  Tablets exceeded  dissolution specification rates for the 10 hour testing point.",
      "recall_initiation_date": "20170203",
      "center_classification_date": "20170314",
      "termination_date": "20180301",
      "report_date": "20170322",
      "code_info": "Lot #160133, 160549 Exp. 08/17  Lot #162006; Exp. 09/17  Lot #163348A, 163348B; Exp. 10/17"
    }
  ]
}